More positive results for Boehringer’s survodutide in MASH

German family-owned pharma major Boehringer Ingelheim has reinforced previously announced data showing that adults treated with survodutide achieved statistically-significant improvement in metabolic dysfunction-associated steatohepatitis (MASH).

At the European Association for the Study of the Liver Congress (EASL) 2024 today, Boehringer announced breakthrough results from a survodutide Phase II trial sub-analysis that demonstrate up to 64.5% of adults with fibrosis stages F2 and F3 (moderate to advanced scarring) achieved an improvement in fibrosis without worsening of MASH, versus 25.9% with placebo after 48 weeks of treatment [response difference: 38.6% (95% CI 18.1% - 59.1%), p=0.0005].F2 and F3 patient populations are at increased risk of developing liver-related complications.3

The secondary endpoint shows that up to 52.3% of adults treated with survodutide (BI 456906) achieved a significant improvement in liver scarring (fibrosis) stages F1, F2 and F3 (mild to moderate or advanced scarring), versus 25.8% with placebo after 48 weeks of treatment [response difference: 26.5% (95% CI 8.37% – 44.66%), p<0.01].1